Skip to main content
Clinical Trials/NCT03363828
NCT03363828
Completed
Not Applicable

The Temporo-spatial Dynamics of Genital Tract Microbiota - an Observational Study in IVF-Freeze All Patients Treated With Estradiol

Peter Humaidan2 sites in 1 country27 target enrollmentOctober 1, 2017
InterventionsEstrofem

Overview

Phase
Not Applicable
Intervention
Estrofem
Conditions
Infertility, Female
Sponsor
Peter Humaidan
Enrollment
27
Locations
2
Primary Endpoint
Rate of ascending infection/sharing of bacteria in the genital tract
Status
Completed
Last Updated
5 years ago

Overview

Brief Summary

The investigators aim to examine the endometrium with state of the art sequencing techniques to investigate the endometrial microbiota. The endometrial microbiota has been perceived to be sterile, however, this seems incorrect from recent studies. Thus, the primary outcome is to compare the rate of ascending infection from the semen to the vagina to the endometrium and to investigate which bacteria are capable of inhabiting these environments. Furthermore, cervical mucus will be obtained in order to test for immunological, microbiological and mechanical properties that may be involved in ascending infection. Finally, the study aim to characterize the temporal changes in the vaginal microbiota during estrogenic treatment with Estrofem® or Vivelle Dot (R) for preparation of the endometrium prior to embryo transfer.

Registry
clinicaltrials.gov
Start Date
October 1, 2017
End Date
January 8, 2021
Last Updated
5 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Peter Humaidan
Responsible Party
Sponsor Investigator
Principal Investigator

Peter Humaidan

Professor

Regionshospitalet Viborg, Skive

Eligibility Criteria

Inclusion Criteria

  • Patients in IVF Freeze-all/segmentation treatment protocol.
  • Written informed consent.

Exclusion Criteria

  • Uterine malformations
  • HIV, Hepatitis B or C positivity. HPV CIN 2 or higher. Chlamydia trachomatis positivity.
  • Any uncontrolled concomitant disease (e.g. uncontrolled diabetes, uncontrolled hypertension etc.)

Arms & Interventions

Abnormal microbiota

Based on qPCR and Next gen sequencing

Intervention: Estrofem

Outcomes

Primary Outcomes

Rate of ascending infection/sharing of bacteria in the genital tract

Time Frame: This outcome data is measured at the day of oocyte retrieval.

Seminal, vaginal, cervical and endometrial samples will be compared at the time of oocyte retrieval.

Secondary Outcomes

  • Number of participants with a Clinical pregnancy(7-9 weeks after inclusion.)
  • Next generation sequencing techniques will be used to assess the vaginal microbiota.I.e. measure of relative abundances(Examined longitudinally throughout the segmentation cycle. The estimated time to event is 40 days from oocyte retrieval until frozen embryo transfer following a strict protocol.)
  • qPCR to assess the vaginal microbiota. I.e. a quantitative measure Copies/mL.(Examined longitudinally throughout the segmentation cycle. The estimated time to event is 40 days from oocyte retrieval until frozen embryo transfer following a strict protocol.)
  • Number of participants with a Live birth(36-42 weeks after inclusion)

Study Sites (2)

Loading locations...

Similar Trials